^
    Back
    Association details:
    Biomarker:EGFR exon 19 deletion + RBM10 S167*
    Cancer:Lung Cancer
    Drug:erlotinib (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    New
    Source:
    bioRxiv
    Title:

    Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR mutant lung cancer

    Excerpt:
    Case #1 harbored the co-occurring mutations EGFR del19 and RBM10 S167* prior to EGFR inhibitor treatment. This patient’s tumor showed only stable disease (SD) on erlotinib therapy (6 months), followed by early progression...
    DOI:
    10.1101/2020.10.26.356352